Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety

Life Sciences

Volumn 88, Issue 15-16, 2011, Pages 730-736

  Yamaori, Satoshi ^a   Ebisawa, Juri ^a   Okushima, Yoshimi ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

9 Tetrahydrocannabinol; Cannabidiol; Cannabinol; CYP3A4; CYP3A5; CYP3A7; Inhibition

Indexed keywords

CANNABIDIOL; CANNABIDIOL DIMETHYL ETHER; CANNABIDIOL METHYL ETHER; CANNABINOL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DILTIAZEM N DEMETHYLASE; DRONABINOL; LIMONENE; METHYLTRANSFERASE; OLIVETOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; IC 50; LIVER MICROSOME; METHYLATION; NONHUMAN;

ARYL HYDROCARBON HYDROXYLASES; CANNABIDIOL; CANNABINOL; CYTOCHROME P-450 CYP3A; DILTIAZEM; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MIDDLE AGED; RESORCINOLS; TETRAHYDROCANNABINOL;

EID: 79953287136     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.02.017     Document Type: Article

References (50)

1. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005;5:595-603. (Pubitemid 40313352)
2. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989;264:10388-95. (Pubitemid 19161599)
3. Aramaki H, Tomiyasu N, Yoshimura H, Tsukamoto H. Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull (Tokyo) 1968;16:822-6.
4. 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 1987;90:315-21.
5. Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 1980;28:115-20. (Pubitemid 10090694)
6. Bornheim LM, Correia MA. Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: a possible member of the cytochrome P- 450IIC subfamily. Mol Pharmacol 1991;40:228-34.
7. 1- tetrahydrocannabinol. Drug Metab Dispos 1992;20:241-6.
8. 8-THC) on hepatic microsomal metabolism of testosterone in vitro. Biochem Pharmacol 1978;27:1725-8.
9. Chen H, Fantel AG, Juchau MR. Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab Dispos 2000;28:1051-7. (Pubitemid 30660359)
10. ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539-48. (Pubitemid 41653504)
11. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of delta9- THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 2000;45:24-30.
12. Fernandes M, Warning N, Christ W, Hill R. Interactions of several cannabinoids with the hepatic drug metabolizing system. Biochem Pharmacol 1973;22:2981-7.
13. Gohda H, Narimatsu S, Yamamoto I, Yoshimura H. In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol. Chem Pharm Bull (Tokyo) 1990;38:1697-701.
14. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53. (Pubitemid 24167278)
15. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006;98:79-85.
16. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-60. (Pubitemid 17204301)
17. 9-tetrahydrocannabinol and cannabidiol on pentobarbital- induced sleeping time and hepatic microsomal drug metabolizing enzyme systems in mice. Yakugaku Zasshi 1983;103:1289-97.
18. Harbison RD, Mantilla-Plata B. Prenatal toxicity, maternal distribution and placental transfer of tetrahydrocannabinol. J Pharmacol Exp Ther 1972;180:446-53.
19. 9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168:657-90.
20. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992;16:276-82.
21. Hurd YL, Wang X, Anderson V, Beck O, Minkoff H, Dow-Edwards D. Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol 2005;27:221-9. (Pubitemid 40279132)
22. Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 1996;26:275-84. (Pubitemid 26128232)
23. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kato R, Kanakubo Y. Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch Biochem Biophys 1985;241:275-80. (Pubitemid 15012034)
24. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kanakubo Y. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem 1987;262:13534-7. (Pubitemid 17144304)
25. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002;30:1108-14.
26. Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M, et al. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 1990;29: 4430-3. (Pubitemid 20153646)
27. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91. (Pubitemid 32268418)
28. Leighty EG. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol 1973;22:1613-21.
29. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007;39:699-721.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
31. McConn II DJ, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 2004;32:1083-91. (Pubitemid 39287581)
32. Means AL, Gudas LJ. The roles of retinoids in vertebrate development. Annu Rev Biochem 1995;64:201-33.
33. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002;42:11S-9S.
34. Molowa DT, Schuetz EG, Wrighton SA, Watkins PB, Kremers P, Mendez-Picon G, et al. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc Natl Acad Sci USA 1986;83:5311-5. (Pubitemid 16051365)
35. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single dose kinetics of cannabidiol in man. In: Agurell S, Dewey WL, Willette R, editors. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. New York: Academic Press; 1984. p. 219-25.
36. 9- tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
37. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83-448. (Pubitemid 34311090)
38. Schuetz JD, Kauma S, Guzelian PS. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 1993;92:1018-24. (Pubitemid 23262427)
39. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23. (Pubitemid 24229655)
40. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration- to-dose ratio in renal transplant recipients. Transplantation 2003;76:1233-5. (Pubitemid 37339651)
41. 8- tetrahydrocannabinol and its metabolites with hepatic microsomal drug metabolizing enzyme systems of mice. J Pharmacobiodyn 1981;4:604-11.
42. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995;18:1138-41.
43. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007;80:1415-9. (Pubitemid 46367067)
44. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002;30:883-91.
45. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75:529-38. (Pubitemid 38746603)
46. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989;36:97-105. (Pubitemid 19191265)
47. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, et al. Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 2003;66:2333-40. (Pubitemid 37456741)
48. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, et al. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004;19:120-9.
49. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79:1691-8.
50. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 1989;320:762-8. (Pubitemid 19093542)